Manufacturing Advantage Singapore based state of the art cell therapy manufacturing facility provides a strong regional supply footprint, enabling faster trial to market timelines and potential manufacturing partnerships or CDMO collaboration for TT11 and TT11X assets.

Funding Momentum Recent financing activity signals robust capital runway, including a round in the hundreds of millions of dollars and a leading Series A, creating favorable conditions for strategic partnerships, co development deals, or license out opportunities around TT11 and TT11X.

Regulatory Momentum RMAT designation from the FDA and PRIME designation by EMA underscore accelerated development pathways, making Tessa an attractive partner for co development, risk sharing deals, or out licensing to advance late stage programs.

Product Portfolio Dual modality portfolio with autologous TT11 and off the shelf TT11X offers multiple BD angles from licensing the allogeneic platform to regional distributors to co development deals with pharma seeking rapid entry into Hodgkin lymphoma and CD30 positive cancers.

APAC Commercial Potential HQ and manufacturing base in Singapore position Tessa as a gateway for Asia Pacific trials and supply agreements, enabling partnerships with regional clinics, hospitals, and biotech or CDMO players looking to access cell therapies in fast growing markets.